Safety of the combination of chloroquine and methylene blue in healthy adult men with G6PD deficiency from rural Burkina Faso (2005)

Peer-Reviewed Study · Mandi G; Witte S; Meissner P; Coulibaly B; Mansmann U; Rengelshausen J; Schiek W; Jahn A; Sanon M; Wüst K; Walter-Sack I; Mikus G; Burhenne J; Riedel KD; Schirmer H; Kouyaté B; Müller O · January 2005

Mandi G et al., 2005-01: Prospective safety study giving a three-day chloroquine plus methylene blue course to 74 G6PD-deficient healthy Burkinabé men. No haemolysis occurred; haemoglobin stayed stable or rose and the regimen was well tolerated.

74 G6PD-deficient but otherwise healthy adult men were given a 3-day oral regimen of a total of 1500 mg CQ and 780 mg MB in the District Hospital of Nouna in north-western Burkina Faso.

Abstract

Mandi G et al., 2005-01: Prospective safety study giving a three-day chloroquine plus methylene blue course to 74 G6PD-deficient healthy Burkinabé men. No haemolysis occurred; haemoglobin stayed stable or rose and the regimen was well tolerated. Study type: open-label prospective clinical trial (safety). N=74 G6PD-deficient healthy adult men, Nouna, Burkina Faso. MB 780 mg total over 3 days (about 13 mg/kg/day at 60 kg) plus chloroquine 1500 mg total, oral. Comparator: none (within-subject baseline). Funder/COI not stated in retrieved record; part of the Heidelberg SFB 544 programme. Authors' own qualification: the population carried predominantly class III G6PD deficiency, so the result does not license use in severe deficiency. Also filed as MTO-26, MTB-28 (claims C1, C13, C3). Study type: uncontrolled series.